226 related articles for article (PubMed ID: 19035787)
1. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns.
Meany DL; Zhang Z; Sokoll LJ; Zhang H; Chan DW
J Proteome Res; 2009 Feb; 8(2):613-9. PubMed ID: 19035787
[TBL] [Abstract][Full Text] [Related]
2. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.
Yoneyama T; Ohyama C; Hatakeyama S; Narita S; Habuchi T; Koie T; Mori K; Hidari KI; Yamaguchi M; Suzuki T; Tobisawa Y
Biochem Biophys Res Commun; 2014 Jun; 448(4):390-6. PubMed ID: 24814705
[TBL] [Abstract][Full Text] [Related]
3. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous analysis of serum α2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer.
Hatano K; Yoneyama T; Hatakeyama S; Tomiyama E; Tsuchiya M; Nishimoto M; Yoshimura K; Miyoshi E; Uemura H; Ohyama C; Nonomura N; Fujita K
Br J Cancer; 2022 Mar; 126(5):764-770. PubMed ID: 34802050
[TBL] [Abstract][Full Text] [Related]
5. O-glycosylated clusterin as a sensitive marker for diagnosing early stages of prostate cancer.
Kazuno S; Fujimura T; Fujime M; Miura Y; Ueno T
Prostate; 2021 Feb; 81(3):170-181. PubMed ID: 33347638
[TBL] [Abstract][Full Text] [Related]
6. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
[No Abstract] [Full Text] [Related]
7. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
8. Development of glycan specific lectin based immunoassay for detection of prostate specific antigen.
Bhanushali PB; Badgujar SB; Tripathi MM; Gupta S; Murthy V; Krishnasastry MV; Puri CP
Int J Biol Macromol; 2016 May; 86():468-80. PubMed ID: 26840176
[TBL] [Abstract][Full Text] [Related]
9. Serum core-type fucosylated prostate-specific antigen index for the detection of high-risk prostate cancer.
Fujita K; Hatano K; Tomiyama E; Hayashi Y; Matsushita M; Tsuchiya M; Yoshikawa T; Date M; Miyoshi E; Nonomura N
Int J Cancer; 2021 Jun; 148(12):3111-3118. PubMed ID: 33594666
[TBL] [Abstract][Full Text] [Related]
10. Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA.
Haga Y; Uemura M; Baba S; Inamura K; Takeuchi K; Nonomura N; Ueda K
Anal Chem; 2019 Feb; 91(3):2247-2254. PubMed ID: 30669833
[TBL] [Abstract][Full Text] [Related]
11. Glycosylation of prostate specific antigen and its potential diagnostic applications.
Vermassen T; Speeckaert MM; Lumen N; Rottey S; Delanghe JR
Clin Chim Acta; 2012 Oct; 413(19-20):1500-5. PubMed ID: 22722018
[TBL] [Abstract][Full Text] [Related]
12. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
15. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.
Mikolajczyk SD; Catalona WJ; Evans CL; Linton HJ; Millar LS; Marker KM; Katir D; Amirkhan A; Rittenhouse HG
Clin Chem; 2004 Jun; 50(6):1017-25. PubMed ID: 15054080
[TBL] [Abstract][Full Text] [Related]
16. Lectin Affinity Chromatography for the Discovery of Novel Cancer Glycobiomarkers: A Case Study with PSA Glycoforms and Prostate Cancer.
Llop E; Peracaula R
Methods Mol Biol; 2022; 2370():301-313. PubMed ID: 34611876
[TBL] [Abstract][Full Text] [Related]
17. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction.
Djavan B; Remzi M; Zlotta AR; Seitz C; Wolfram R; Hruby S; Bursa B; Schulman CC; Marberger M
Tech Urol; 1999 Jun; 5(2):71-6. PubMed ID: 10458658
[TBL] [Abstract][Full Text] [Related]
18. Aberrant PSA glycosylation--a sweet predictor of prostate cancer.
Gilgunn S; Conroy PJ; Saldova R; Rudd PM; O'Kennedy RJ
Nat Rev Urol; 2013 Feb; 10(2):99-107. PubMed ID: 23318363
[TBL] [Abstract][Full Text] [Related]
19. Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer.
Fujita K; Hayashi T; Matsuzaki K; Nakata W; Masuda M; Kawashima A; Ujike T; Nagahara A; Tsuchiya M; Kobayashi Y; Nojima S; Uemura M; Morii E; Miyoshi E; Nonomura N
Oncotarget; 2016 Aug; 7(35):56643-56649. PubMed ID: 27494861
[TBL] [Abstract][Full Text] [Related]
20. Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays.
Li Y; Tao SC; Bova GS; Liu AY; Chan DW; Zhu H; Zhang H
Anal Chem; 2011 Nov; 83(22):8509-16. PubMed ID: 21975078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
